Rockwell Medical (NASDAQ:RMTI) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Rockwell Medical (NASDAQ:RMTI) in a report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock.

Separately, StockNews.com raised Rockwell Medical from a sell rating to a hold rating in a report on Wednesday, June 19th.

Rockwell Medical Price Performance

Shares of NASDAQ RMTI opened at $3.88 on Wednesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.60 and a current ratio of 2.00. The company has a market cap of $120.24 million, a PE ratio of -10.76 and a beta of 1.47. The business has a 50-day simple moving average of $2.50 and a two-hundred day simple moving average of $1.95. Rockwell Medical has a fifty-two week low of $1.16 and a fifty-two week high of $4.38.

Rockwell Medical (NASDAQ:RMTI) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.05. Rockwell Medical had a negative return on equity of 6.96% and a negative net margin of 5.06%. The business had revenue of $25.83 million during the quarter, compared to the consensus estimate of $23.01 million. During the same quarter last year, the company earned ($0.18) earnings per share. As a group, equities analysts expect that Rockwell Medical will post -0.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Rockwell Medical

Institutional investors and hedge funds have recently modified their holdings of the company. Armistice Capital LLC raised its position in Rockwell Medical by 22.5% during the second quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock valued at $5,670,000 after acquiring an additional 592,000 shares in the last quarter. Vanguard Group Inc. raised its position in Rockwell Medical by 4.0% during the first quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company’s stock valued at $1,856,000 after acquiring an additional 43,302 shares in the last quarter. Renaissance Technologies LLC raised its position in Rockwell Medical by 877.1% during the second quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock valued at $181,000 after acquiring an additional 92,189 shares in the last quarter. Finally, SkyOak Wealth LLC raised its position in Rockwell Medical by 47.3% during the first quarter. SkyOak Wealth LLC now owns 25,110 shares of the company’s stock valued at $42,000 after acquiring an additional 8,065 shares in the last quarter. Institutional investors and hedge funds own 23.31% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.